| Similar Articles |
|---|
 |
The Motley Fool
April 24, 2007
Brian Lawler |
MedImmune Not Immune to Takeovers MedImmune shops itself to AstraZeneca. MedImmune investors appear to be getting a pretty sweet deal.   |
The Motley Fool
February 1, 2008
Brian Lawler |
AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs. |
The Motley Fool
October 14, 2010
Sean Williams |
Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away. |
The Motley Fool
April 2, 2008
Brian Lawler |
Bad Timing for AstraZeneca's Good Data AstraZeneca quietly reports a successful clinical study for its cholesterol-lowering lead drug. |
The Motley Fool
October 26, 2006
Brian Lawler |
Market Rejects AstraZeneca's Remedy Investors pummel the pharmaceutical firm, despite its impressive results. |
Chemistry World
April 24, 2007
Victoria Gill |
AstraZeneca Scoops up $15.6 Billion Vaccine Business AstraZeneca has joined the race to scoop up acquisition opportunities in the biologics sector with a $15.6 billion deal to buy U.S. vaccines and biotechnology company MedImmune. |
The Motley Fool
April 30, 2010
Brian Orelli |
Living the Blockbuster Model AstraZeneca's top drugs provide top-line growth in the first quarter. |
The Motley Fool
July 30, 2007
Brian Lawler |
AstraZeneca's Yawner of a Quarter The pharma's second-quarter results are ho-hum. Investors may do well to take a look at some of the other big pharma stocks, which offer more compelling reasons to buy. |
The Motley Fool
February 5, 2007
Billy Fisher |
A Fresh Outlook at AstraZeneca Strong performance makes management happy at the European drug giant. As long as the company is able to continue the strong revenue growth from its major contributors, shareholders will be able to enjoy a prosperous 2007. |
The Motley Fool
October 30, 2008
Brian Orelli |
What's on Deck for AstraZeneca? The drugmaker increases EPS by cutting costs, but it's the next move that will count the most. |
The Motley Fool
August 20, 2007
Brian Lawler |
Are These Perfect Pharma Acquisitions? Weighing recent drug-industry deals' odds of success: AstraZeneca and MedImmune... Shire and New River Pharmaceuticals... Gilead and Myogen... |
The Motley Fool
December 28, 2005
Stephen D. Simpson |
AstraZeneca, Reloaded In an attempt to shore up a soft pipeline, AstraZeneca has gotten very busy looking for partners. Investors, this is not the most attractive stock in the sector, but not a horrible pick, either. |
The Motley Fool
January 28, 2011
Alan Oscroft |
AstraZeneca to Double Buybacks Regulatory setbacks have hit the drug firm's profits, but things look pretty resilient overall. |
The Motley Fool
April 13, 2007
Brian Lawler |
MedImmune Wants a Mate The biopharma announces the hiring of investment bankers to look for a possible acquirer. Investors, take note. |
The Motley Fool
January 27, 2005
Stephen D. Simpson |
AstraZeneca Shines, for Now The British-Swedish drug company has a great quarter, but the future looks dimmer. |
The Motley Fool
August 31, 2010
Brian Orelli |
A Mostly Meaningless FDA Rejection The Food and Drug Administration sends AstraZeneca back to the drawing board for the second time when it rejected motavizumab, the drugmaker's newest treatment for respiratory syncytial virus. |
The Motley Fool
October 30, 2009
Brian Orelli |
Of One-Time Gains and Pipelines AstraZeneca's earnings report illustrates the nature of polar opposites with one-time gains and new drugs. One is to be largely ignored, while the other will drive the drugmaker's future. |
The Motley Fool
July 30, 2010
Cliff D'Arcy |
Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline. |
The Motley Fool
July 27, 2010
Brian Orelli |
Brilinta? I Think Not. AstraZeneca's new blood thinner is far from brilliant. |
The Motley Fool
July 27, 2006
Stephen D. Simpson |
AstraZeneca Needs a Rest The stock isn't too expensive, but it's no longer a bargain. |
The Motley Fool
September 25, 2007
Billy Fisher |
Bristol-Myers Buys In to Biologics Looking to advance its biologics strategy, Bristol-Myers Squibb announces it will acquire Adnexus Therapeutics, a privately held developer of biologics. |
BusinessWeek
January 31, 2005
Kerry Capell |
No Relief For AstraZeneca More bad news about potential blockbusters weakens Europe's third-largest drugmaker. Analysts say the only thing keeping Astra's shares from going into free fall is the mounting speculation that GSK might make a play for the troubled drugmaker. |
The Motley Fool
March 1, 2004
Alyce Lomax |
MedImmune Under the Weather After short-term setbacks, the biotech turns to the long term. |
The Motley Fool
August 3, 2006
S.J. Caplan |
AstraZeneca's Path to Avoid Pain The pharmaceutical giant partners with Pozen to co-develop a drug. Take heart, AstraZeneca shareholders! No queasy stomachs are expected in your future. |
The Motley Fool
July 23, 2007
Brian Lawler |
Medarex Cheering for Its Partner The biopharma's partner advances one of its compounds into later stage clinical testing. Investors, take note. |
The Motley Fool
November 20, 2008
Brian Orelli |
Double Trouble for AstraZeneca A double dose of bad news for AstraZeneca. Current revenue is vanishing, and potential revenue is failing to materialize. |
The Motley Fool
July 29, 2010
Brian Orelli |
This FDA Panel Isn't Brilliant Why does AstraZeneca's blood thinner Brilinta work better outside the U.S. than here at home? The Food and Drug Administration's advisory panel didn't seem to have a good explanation, but they didn't appear to care much, either. |
The Motley Fool
April 12, 2004
Charly Travers |
Bargain Hunting in Big Biotech MedImmune's recent FluMist troubles may have created a buying opportunity for long-term investors. |
The Motley Fool
February 2, 2006
Stephen D. Simpson |
AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here. |
The Motley Fool
October 27, 2005
Stephen D. Simpson |
AstraZeneca Prepares for a Dry Spell A weak late-stage pipeline will make for challenging earnings growth in the coming years. Investors may want to hold out for a better price here. |
The Motley Fool
April 24, 2007 |
AstraZeneca Swells Net Sales: Fool by Numbers The pharmaceutical released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 11, 2007
Brian Lawler |
MedImmune Brings Home the Bacon The drugmaker announces preliminary first-quarter financial results. |
Chemistry World
December 24, 2015
Jennifer Newton |
AstraZeneca to buy Acerta for blood cancer drug AstraZeneca has agreed to buy a majority stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US. |
Chemistry World
September 17, 2007 |
Uk Pharma Shifts Manufacturing Overseas Drug firm AstraZeneca has today reiterated that it will outsource drug manufacturing. |
The Motley Fool
October 11, 2011
Cliff D'Arcy |
AstraZeneca Loves This $100Bn Market The British pharma firm makes its largest-ever manufacturing investment -- in China. |
The Motley Fool
August 5, 2005
Charly Travers |
No Surprise Over PDL's Upside Protein Design Labs' overwhelmingly positive earnings release is good news for shareholders. |
The Motley Fool
May 18, 2011
Frank Vinluan |
Targacept's $75M Stock Offering Targets Cognitive Disorders R&D AstraZeneca bailed, but Targacept keeps on trucking. |
Chemistry World
December 20, 2013
Patrick Walter |
AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture. |
Chemistry World
February 2, 2012
Andrew Turley |
AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term. |
Chemistry World
January 28, 2010
Nina Notman |
AstraZeneca's workforce slashed again Pharma giant AstraZeneca is to cut another 8,000 jobs globally over the next four years - with approximately 1,800 additional research and development staff to be lost. |
The Motley Fool
April 21, 2005
Charly Travers |
Synagis Has Some Legs Left The mature drug still generates big numbers for MedImmune. Investors, take note. |
The Motley Fool
January 8, 2010
Brian Orelli |
Heartburn Relieved ... for Now AstraZeneca settles its patent dispute with Teva. |
BusinessWeek
June 2, 2011
Kresge & Connolly |
A New Pricing Game for Drugmakers in Europe Germany's new rules tying pharmaceutical prices to greater efficacy is worrying companies. |
The Motley Fool
May 21, 2009
Robert Steyer |
The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations? |
The Motley Fool
May 3, 2010
Brian Orelli |
While You Were Reveling in Dendreon's Win The FDA has approved Vimovo, an arthritis drug from Pozen and AstraZeneca, and Bristol-Myers Squibb also got a decision from the FDA, but it wasn't the positive kind. |
The Motley Fool
April 24, 2007
Brian Lawler |
AtheroGenics Loses a Partner The specialty drug maker's drug-development partner bails. Waiting around for years on more clinical trial results for a drug with such unproven efficacy is not something that is a recipe for success with specialty pharma stock investing. |
The Motley Fool
May 15, 2006
Brian Gorman |
AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note. |
Chemistry World
March 19, 2013
Simon Hadlington |
Global AstraZeneca restructuring will cost 1600 jobs The company's global research blueprint will now be centered on the creation of three 'strategic R&D centers' for small molecules and biologics, to be based in Cambridge in the UK, Gaithersburg in Maryland, US, and Molndal in Sweden, to be completed by 2016. |
The Motley Fool
November 26, 2008
Brian Orelli |
Teva and AstraZeneca's Drama Concludes Teva and AstraZeneca settle a lawsuit, but investors are still left in the dark. |
The Motley Fool
November 2, 2011
Prabhat Sakya |
AstraZeneca vs. GlaxoSmithKline If you could only invest in one of these companies, which would it be? |
